1. Home
  2. CRGX vs JQC Comparison

CRGX vs JQC Comparison

Compare CRGX & JQC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRGX
  • JQC
  • Stock Information
  • Founded
  • CRGX 2021
  • JQC 2003
  • Country
  • CRGX United States
  • JQC United States
  • Employees
  • CRGX N/A
  • JQC N/A
  • Industry
  • CRGX
  • JQC Finance Companies
  • Sector
  • CRGX
  • JQC Finance
  • Exchange
  • CRGX Nasdaq
  • JQC Nasdaq
  • Market Cap
  • CRGX 964.5M
  • JQC 800.1M
  • IPO Year
  • CRGX 2023
  • JQC N/A
  • Fundamental
  • Price
  • CRGX $12.81
  • JQC $5.74
  • Analyst Decision
  • CRGX Strong Buy
  • JQC
  • Analyst Count
  • CRGX 6
  • JQC 0
  • Target Price
  • CRGX $31.80
  • JQC N/A
  • AVG Volume (30 Days)
  • CRGX 229.0K
  • JQC 714.6K
  • Earning Date
  • CRGX 11-12-2024
  • JQC 01-01-0001
  • Dividend Yield
  • CRGX N/A
  • JQC 11.13%
  • EPS Growth
  • CRGX N/A
  • JQC N/A
  • EPS
  • CRGX N/A
  • JQC N/A
  • Revenue
  • CRGX N/A
  • JQC N/A
  • Revenue This Year
  • CRGX N/A
  • JQC N/A
  • Revenue Next Year
  • CRGX N/A
  • JQC N/A
  • P/E Ratio
  • CRGX N/A
  • JQC N/A
  • Revenue Growth
  • CRGX N/A
  • JQC N/A
  • 52 Week Low
  • CRGX $12.58
  • JQC $4.82
  • 52 Week High
  • CRGX $33.92
  • JQC $5.65
  • Technical
  • Relative Strength Index (RSI)
  • CRGX 30.99
  • JQC 38.74
  • Support Level
  • CRGX $13.33
  • JQC $5.82
  • Resistance Level
  • CRGX $15.26
  • JQC $5.82
  • Average True Range (ATR)
  • CRGX 1.36
  • JQC 0.05
  • MACD
  • CRGX -0.30
  • JQC -0.02
  • Stochastic Oscillator
  • CRGX 3.51
  • JQC 6.09

About CRGX CARGO Therapeutics Inc.

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.

About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.

Share on Social Networks: